ASH 2021 | POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCL
John Burke, MD, Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, presents findings from the Phase III POLARIX trial (NCT03274492), which assessed polatuzumab vedotin, an antibody-drug conjugate, with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) in patients with diffuse large B-cell lymphoma (DLBCL). Patients were randomized to receive either polatuzumab vedotin with R-CHP or the current standard of care, R-CHOP (R-CHP with vincristine), with the primary endpoint being progression-free survival. Polatuzumab vedotin significantly improved PFS compared to R-CHOP, and reduced the rate of relapse. A toxicity profile similar to that of the standard of care was additionally reported. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
